Linderae Radix Ethanol Extract Alleviates Diet-Induced Hyperlipidemia by Regulating Bile Acid Metabolism Through gut Microbiota.
bile acid metabolism
enterohepatic circulation
gut microbiota
hyperlipidemia
lipid metabolism
natural drug
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
11
2020
accepted:
12
01
2021
entrez:
8
3
2021
pubmed:
9
3
2021
medline:
9
3
2021
Statut:
epublish
Résumé
Hyperlipidemia is a common metabolic disorder and regarded as one of the main risk factors for cardiovascular disease. The gut microbiota has been identified as a potential contributor to hyperlipidemia as it can greatly regulate bile acid metabolism. Linderae radix is a natural medicine widely used in the treatment of a variety of diseases and is also a common drug for hyperlipidemia. Recently, the lipid-lowering effect of Linderae radix are receiving increasing attention but the underlying mechanism remains unknown. The study aimed to investigate the effects of Linderae radix ethanol extract (LREE) on gut microbiota in rats with hyperlipidemia syndrome. We established a hyperlipidemia rat model using a high-fat diet and used LREE as the intervention. Blood lipid levels and pathological examination were measured to assess the effects of LREE on hyperlipidemia. The gut microbiota was determined by 16s rDNA sequencing and the bile acid metabolism-related proteins were detected by western blot to discover the underlying correlations. The results show that LREE lowered TC, TG, and LDL levels effectively, and it also alleviated liver injury by reducing ALT and AST activity. Meanwhile, LREE improved gut microbiota disturbance caused by HFD via increasing intestinal microbiota diversity and changing the abundance of the Firmicutes, Bacteroidetes, and Actinobacteria. In addition, LREE can increase bile acid reabsorption and promote fecal excretion through farnesoid X receptor (FXR), apical sodium-dependent bile acid transporter (ASBT), organic solute transporter alpha (OST-α), and cytochrome P450 family 7 Subfamily A Member 1 (CYP7A1) thus restoring abnormal bile acid metabolism caused by hyperlipidemia.
Identifiants
pubmed: 33679408
doi: 10.3389/fphar.2021.627920
pii: 627920
pmc: PMC7925880
doi:
Types de publication
Journal Article
Langues
eng
Pagination
627920Informations de copyright
Copyright © 2021 Jiang, Xu, Liu, Liu, Wang, Jiang, Zhang, Yang, Huang and Lou.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Diabetologia. 2007 Nov;50(11):2374-83
pubmed: 17823788
J Agric Food Chem. 2020 Jan 8;68(1):147-159
pubmed: 31826616
Annu Rev Biochem. 2003;72:137-74
pubmed: 12543708
J Ethnopharmacol. 2012 Mar 27;140(2):345-67
pubmed: 22306102
Org Lett. 2010 Jul 16;12(14):3196-9
pubmed: 20545338
Nutrients. 2020 May 19;12(5):
pubmed: 32438689
N Engl J Med. 2014 Apr 10;370(15):1422-31
pubmed: 24645848
Science. 1999 May 21;284(5418):1365-8
pubmed: 10334993
Int J Endocrinol. 2020 Sep 14;2020:8601796
pubmed: 33005189
Expert Opin Drug Discov. 2011 Oct;6(10):995-1025
pubmed: 22646861
Phytomedicine. 2010 Aug;17(10):726-31
pubmed: 20363113
Child Obes. 2018 Nov/Dec;14(8):501-509
pubmed: 30183336
Science. 2018 Mar 9;359(6380):1151-1156
pubmed: 29590046
Int J Cancer. 2016 Oct 15;139(8):1764-75
pubmed: 27273788
Pharmacol Ther. 2018 Nov;191:162-177
pubmed: 29933033
Dig Liver Dis. 2018 Jul;50(7):635-639
pubmed: 29650468
JAMA. 2016 Nov 15;316(19):1997-2007
pubmed: 27838723
Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15718-23
pubmed: 15505215
Circulation. 2016 Jan 26;133(4):e38-360
pubmed: 26673558
Curr Atheroscler Rep. 2020 Jun 3;22(7):26
pubmed: 32494971
Nature. 2010 Mar 4;464(7285):59-65
pubmed: 20203603
J Ethnopharmacol. 2007 May 4;111(2):322-8
pubmed: 17204385
Nat Methods. 2013 Oct;10(10):996-8
pubmed: 23955772
Hepatology. 2005 Dec;42(6):1270-9
pubmed: 16317684
Nature. 2014 Jan 23;505(7484):559-63
pubmed: 24336217
J Clin Invest. 2003 Dec;112(12):1821-30
pubmed: 14679177
Appl Environ Microbiol. 2007 Aug;73(16):5261-7
pubmed: 17586664
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
Lancet. 2012 Aug 11;380(9841):581-90
pubmed: 22607822
ISME J. 2012 May;6(5):1046-57
pubmed: 22170424
Protein Cell. 2020 Nov 30;:
pubmed: 33252713
Bioinformatics. 2011 Nov 1;27(21):2957-63
pubmed: 21903629
Trends Biochem Sci. 2006 Oct;31(10):572-80
pubmed: 16908160
Science. 2011 Oct 7;334(6052):105-8
pubmed: 21885731
BMC Microbiol. 2017 May 22;17(1):120
pubmed: 28532414
Nat Rev Endocrinol. 2019 Feb;15(2):69-70
pubmed: 30602737
J Proteome Res. 2015 Feb 6;14(2):850-9
pubmed: 25581415
Nat Rev Microbiol. 2021 Jan;19(1):55-71
pubmed: 32887946
Gastroenterology. 1979 Aug;77(2):223-30
pubmed: 447035
Dig Dis. 2015;33(3):327-31
pubmed: 26045265
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13580-5
pubmed: 18757757
J Nutr. 2013 Apr;143(4):417-23
pubmed: 23343669
Atherosclerosis. 2000 Nov;153(1):59-67
pubmed: 11058700
Dtsch Arztebl Int. 2016 Jul 1;113(26):445-53
pubmed: 27412989
Biomed Res Int. 2014;2014:925302
pubmed: 25110708
J Hepatol. 2015 Sep;63(3):697-704
pubmed: 26022694
Chem Pharm Bull (Tokyo). 2007 Sep;55(9):1390-2
pubmed: 17827769
Drug Saf. 2011 Jan 1;34(1):1-19
pubmed: 21142270
Rev Endocr Metab Disord. 2019 Dec;20(4):461-472
pubmed: 31707624